High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience by A.J. Piper-Vallillo, MD, Julia K. Rotow, MD, Jacqueline V. Aredo, MD, Khvaramze Shaverdashvili, MD, PhD, Jia Luo, MD, Jennifer W. Carlisle, MD, Hatim Husain, MD, Alona Muzikansky, MA, Rebecca S. Heist, MD, Deepa Rangachari, MD, Suresh S. Ramalingam, MD, Heather A. Wakelee, MD, Helena A. Yu, MD, Lecia V. Sequist, MD, Joshua M. Bauml, MD, Joel W. Neal, MD, PhD, Zofia Piotrowska, MD, MHS

Get full text

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study by Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS

Get full text

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC by Jacqueline V. Aredo, MD, MS, Heather A. Wakelee, MD, Kavitha J. Ramchandran, MD, Joel W. Neal, MD, PhD, Maximilian Diehn, MD, PhD, Angela Bik-Yu Hui, PhD, Ameen Salahudeen, MD, PhD, Bernice Kwong, MD, Gerald J. Berry, MD, H. Henry Guo, MD, PhD, Kristen Cunanan, PhD, Shireen Vali, PhD, Danny Pancirer, BA, Vivian Tsang, MSN, Grace Hwang, MS, Monica Loza, BA, Brittany Johnson, BA, Isabelle Blanchard, BS, Sukhmani K. Padda, MD

Get full text